Skip to main content
Premium Trial:

Request an Annual Quote

Med Fusion, GenomOncology Partner to Provide Clinical Analyses of Patient Tumors

NEW YORK (GenomeWeb) – Med Fusion and GenomOncology have partnered to provide genomic profiles of patient tumors for treatment guidance and clinical trial enrollment, the companies said today.

Under the agreement, Med Fusion, a clinical service laboratory and clinical trials service organization based in Lewisville, Texas, will combine its solid tumor panels with GenomOncology's GO Clinical Workbench platform, a decision support tool that interprets tumor sequence data and translates molecular profiles into clinical reports.

Med Fusion said it plans to launch several disease-specific solid tumor panels, including for non-small cell lung cancer and colorectal cancer, early in the third quarter.

GenomOncology, located in Cleveland, will use the GO Clinical Workbench to interpret next-generation sequencing data from the tumors, in conjunction with other factors, to create reports and provide rules-based decision support for clinical data interpretation.

"Increased understanding of the underlying genetic changes that may be driving tumor growth or metastasis can enable precise treatment strategies tailored to the genetic profile of each patient's cancer," said Tom Lohmann, chief medical officer of Med Fusion, in a statement.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.